Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

@article{Fandy2009EarlyEC,
  title={Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.},
  author={Tamer Fandy and James G. Herman and Patrick W Kerns and Anchalee Jiemjit and Elizabeth A. Sugar and Si-Ho Choi and Allen S. Yang and Timothy J. Aucott and Tianna Dauses and Rosalie Odchimar-Reissig and Jonathan Licht and Melanie Jane McConnell and Chris A. Nasrallah and Marianne K-H Kim and Weijia Zhang and Yezou Sun and Anthony J. Murgo and Igor Espinoza-Delgado and Katharine E Oteiza and Ibitayo Owoeye and Lewis R. Silverman and Steven D Gore and Hetty E. Carraway},
  journal={Blood},
  year={2009},
  volume={114 13},
  pages={2764-73}
}
Sequential administration of DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors has demonstrated clinical efficacy in patients with hematologic malignancies. However, the mechanism behind their clinical efficacy remains controversial. In this study, the methylation dynamics of 4 TSGs (p15(INK4B), CDH-1, DAPK-1, and SOCS-1) were studied in sequential bone marrow samples from 30 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 116 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

CDKN 2 B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5 - azacyti - dine

G Garcia-Manero, HM Kantarjian, B Sanchez-Gonzalez
Leukemia . • 2007

Similar Papers

Loading similar papers…